Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis. With the clinical trial demonstrating a doubling in the ...

Oral polysaccharide-engineered nanozyme treats colitis-linked mental disorders by targeting oxidative stress and gut ...

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes chronic inflammation and ulcers in the innermost ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Roivant Sciences (NASDAQ:ROIV) is close to selling its ulcerative colitis drug candidate RVT-3101 to Roche (OTCQX:RHHBY) through a deal that could be worth more than $7B, according to The Wall Street ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...